Drug: ambrisentan

Manufacturer: Gilead

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication: to improve exercise ability and delay clinical worsening in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening WHO group 1 pulmonary arterial hypertension

Disease: pulmonary arterial hypertension

Therapeutic Area: Pulmonary

Enrollment Form Link: N/A

Phone Number: N/A

Fax Number: N/A

Product Website: letairis.com